Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5434403

CCOc1ccccc1CN1CCC2(CC1)CCN(C(=O)c1cccc(N(C)C)c1)CC2.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.59
TSHR P16473 5/20 0.56
USP2 O75604 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CHRM2 P08172 2/20 0.52
CHRM3 P20309 2/20 0.52
CCR8 P51685 7/20 0.51
KCNH2 Q12809 7/20 0.51
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 4/20 0.51
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399254 0.95 CYP2D6 (0.62) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5434658 0.92 CYP2D6 (0.57) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5431615 0.91 CYP2D6 (0.58) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5431336 0.89 CCR8 (0.62) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5433719 0.88 USP2 (0.67) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5439858 0.87 CYP2D6 (0.65) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5430883 0.87 CYP2D6 (0.60) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
SCHEMBL5431253 0.87 CYP2D6 (0.59) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5428831 0.86 CYP2D6 (0.58) CYP2D6TSHRUSP2SMN1; SMN2CHRM2
Trifluoroacetic Acid SCHEMBL5428508 0.85 TSHR (0.58) CYP2D6TSHRUSP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases CCR8, CCR1, CCR10 CYP2D6 1764/4885TSHR 3697/4885USP2 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.